White label ELPA - ClinicalTrials.eu

Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

Not recruiting

2 1
Investigated diseases:
- Partial seizures
Investigated drugs:
- Azetukalner
Study on Gene Therapy for Pyruvate Kinase Deficiency Using Autologous CD34+ Cells in Adults and Children

Not recruiting

1 1 1 1
Investigated diseases:
- Pyruvate kinase deficiency anaemia
Investigated drugs:
Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Not recruiting

3 1 1
Investigated diseases:
- Demyelination
Investigated drugs:
- Rozanolixizumab
+4
Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

Not recruiting

2 1 1
Investigated diseases:
Investigated drugs:
- Amg 193
Study on the Safety and Effectiveness of Crofelemer for Children with Microvillus Inclusion Disease (MVID)

Not recruiting

2 1
Investigated diseases:
- Microvillous inclusion disease
Investigated drugs:
- Crofelemer
Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

Not recruiting

3 1 1 1
Investigated diseases:
- Coagulopathy
Investigated drugs:
Study on the Effectiveness of Lenvatinib for Patients with Advanced Gastrointestinal Stromal Tumors After Imatinib and Sunitinib Treatment Failure

Not recruiting

2 1 1
Investigated diseases:
- Gastrointestinal stromal tumour
Investigated drugs:
- Lenvatinib
Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Not recruiting

3 1 1
Investigated diseases:
- Endometrial cancer
Investigated drugs:
+2
Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

Not recruiting

2 1 1 1
Investigated diseases:
- B-cell lymphoma refractory
Investigated drugs:
Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Not recruiting

3 1 1 1
Investigated diseases:
- Cholangiocarcinoma
Investigated drugs:
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies